Evgen Pharma plc (LON: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, have announced today that Steve Franklin, the Company’s CEO, will be presenting tomorrow evening at a ShareSoc Growth Company Seminar in Manchester.
In the presentation, Steve Franklin will outline the Company’s proprietary technology and describe its two on-going Phase II trials in metastatic breast cancer and subarachnoid haemorrhage. He will also answer any questions from investors.
The ShareSoc event, which is primarily for private investors, starts at 5.30pm on 20 November 2018 and is being held at the DoubleTree by Hilton Hotel, One Piccadilly Place, 1 Auburn Street, Manchester M1 3DG.
Further details of the event, along with a registration form, are available at this link:
ShareSoc Growth Company Seminar in Manchester, 20 November 2018
Evgen Pharma plc is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company’s core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Evgen commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
